CURE has recently continued that trend of topping its underlying index by more than it should be. The ETF’s 30-day variance against triple the returns of the underlying index is 4.6%, according to Direxion data. Only five of Direxion’s leveraged bullish ETFs have beaten their indexes by more over the same period.
CURE’s stellar performance and docile-by-comparison reputation relative to other leveraged ETFs have sent investors flocking to the fund. Last May, CURE became a $100 million ETF. Year-to-date, CURE has added $20 million in new assets, propelling the ETF to $300 million in AUM. [A Rush to Leveraged Health Care ETFs]
Direxion Daily Healthcare Bull 3x Shares
